Predictive power is the toughest metric in in vitro detection that takes false signals into full account.  Industry officials and company officers seem to prefer to cite the term “sensitivity” perhaps in part because even highly sensitive proteomic tests do not excel. The estimated range of predictive power for the many companies in the industry is believed to be no more than 80-85% for the top tier. OTraces may be raising this industry standard 95%-plus and filed patents that management believes should cover on all known routes to this achievement.

OTraces blood-based disease detection system harnesses math-based and measurement science software and algorithms, not unlike those techniques used in other fields like space communications to resolve signal complexity that have never been used in biological testing. OTraces has modified and refined these techniques as necessary to address the unique challenges of cancer detection with remarkable results.  OTraces has averaged predictive power of 95%-plus in over 2,000 tests for detecting multiple cancer tumor types, and even higher levels have been reached in validation trials for the company’s breast and prostate cancer screening tests now underway.

OTraces has filed for patent protection covering all known pathways to the enhancement of predictive power to these levels.  This strengthens the growth potential and market acceptance of its cancer screening tests, but also opens up many opportunities to license access to its software in non-core areas to other companies and CLIA labs in the U.S. and abroad should be extensive.

Whereas companies in the industry usually embed their software into the instruments themselves, OTraces uses FDA-compliant archival software and secure cloud based transmissions so that all data from the company’s CDx (instrument) system can be collected and securely stored on in the company’s U.S. based servers.    Applying feedback from the installed base, input from key institutions about patient outcomes, allows OTraces to collect data for clearance submissions in other markets.  These data are available in real time as the tests are run in the field.

The software is comprised of patented algorithms that enhance predictive power.  It is domiciled in the company’s LIMS in a secure U.S. server network.

The cancer score generated by these algorithms is sent back to the prescribing physician anywhere in the world using an FDA-compliant LIMS that serves as the exclusive repository of all patient data.